Biggest News Aggregation in the World
๐Ÿ“ฐ Published March News

Page 23 - Published March News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Published March. Real-time updates on events, politics, business and more.

ULM Speech-Language Pathology to host 35th Annual Spring Conference, Mar. 9-10

The Speech-Language Pathology Program and the Kitty DeGree Speech and Hearing Center at the University of Louisiana Monroe invite the public to attend the 35th Annual Spring Conference on March 9-10 at Bayou Pointe Event Center. Dr. Amanda Stead, Associate Professor, Speech-Language Pathologist, and Coordinator of Simulation Education at Pacific University in the School of Communication Sciences and Disorders, will be speaking on Evidence-Based Tools for Working in Dementia Care and in End-of-L...
University Of Louisiana Monroe United States Pacific University Language Pathology Program Hearing Center Hearing Association
Source: ulm.edu

ULM Mock Trial Team returns to ORCS

After a 2-year absence during COVID, the ULM Mock Trial Maroon team has advanced to the Opening Round Championship Series (ORCS,) the second round of the American Mock Trial Associationโ€™s national tournament. The team secured their spot in the ORCS after earning the second-highest team ranking at the Houston Regional Tournament from February 17-19.
United States Madisyn Rideau Anthony Trejo Chloe Dustin Maggie Eubanks Katie Meno
Source: ulm.edu

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Novartis Pharma AG: Novartis Kisqali prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2- metastatic breast cancer compared to chemotherapy

RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2- metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus endocrine
United States New Jersey San Antonio East Hanover Comunidad Autonoma De Cataluna Richard Jarvis

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
United States New Jersey San Antonio East Hanover Comunidad Autonoma De Cataluna Richard Jarvis

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science